From GlobeNewswire:

Dyne Therapeutics announces the pricing of an underwritten public offering of 17,150,000 shares of its common stock at a public offering price of $17.50 per share. Expected gross proceeds are approximately $300.1 million. Dyne also grants the underwriters a 30-day option to purchase up to an additional 2,572,500 shares of its common stock. The offering is expected to close on or about January 9, 2024. Four companies are acting as joint book-running managers for the offering, with two acting as co-managers. The offering is being made pursuant to a shelf registration statement on Form S-3. Dyne Therapeutics is a clinical-stage muscle disease company with a proprietary FORCE™ platform. This press release contains forward-looking statements regarding the public offering. Dyne’s stock is listed on the Nasdaq exchange under the ticker symbol DYN. For more information, contact Investor Amy Reilly at [email protected] or 857-341-1203. For media inquiries, contact Stacy Nartker at [email protected] or 781-317-1938.



Read more: Dyne Therapeutics Announces Pricing of $300 Million Public